262 related articles for article (PubMed ID: 19259064)
21. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
22. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
23. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
24. Delivery of full-length factor VIII using a piggyBac transposon vector to correct a mouse model of hemophilia A.
Matsui H; Fujimoto N; Sasakawa N; Ohinata Y; Shima M; Yamanaka S; Sugimoto M; Hotta A
PLoS One; 2014; 9(8):e104957. PubMed ID: 25126862
[TBL] [Abstract][Full Text] [Related]
25. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of Hemophilia A.
Matsui H; Hegadorn C; Ozelo M; Burnett E; Tuttle A; Labelle A; McCray PB; Naldini L; Brown B; Hough C; Lillicrap D
Mol Ther; 2011 Apr; 19(4):723-30. PubMed ID: 21285959
[TBL] [Abstract][Full Text] [Related]
26. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
[TBL] [Abstract][Full Text] [Related]
27. Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer.
Kang Y; Xie L; Tran DT; Stein CS; Hickey M; Davidson BL; McCray PB
Blood; 2005 Sep; 106(5):1552-8. PubMed ID: 15886327
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow stromal cells as targets for gene therapy of hemophilia A.
Chuah MK; Brems H; Vanslembrouck V; Collen D; VandenDriessche T
Hum Gene Ther; 1998 Feb; 9(3):353-65. PubMed ID: 9508053
[TBL] [Abstract][Full Text] [Related]
29. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
Sun J; Hua B; Chen X; Samulski RJ; Li C
Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
[TBL] [Abstract][Full Text] [Related]
30. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
31. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.
Scallan CD; Liu T; Parker AE; Patarroyo-White SL; Chen H; Jiang H; Vargas J; Nagy D; Powell SK; Wright JF; Sarkar R; Kazazian HH; McClelland A; Couto LB
Blood; 2003 Dec; 102(12):3919-26. PubMed ID: 12893764
[TBL] [Abstract][Full Text] [Related]
32. Hemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche T; Chuah MK
Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
[TBL] [Abstract][Full Text] [Related]
33. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
[TBL] [Abstract][Full Text] [Related]
34. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
35. Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A.
Yamaki Y; Fukushima T; Yoshida N; Nishimura K; Fukuda A; Hisatake K; Aso M; Sakasai T; Kijima-Tanaka J; Miwa Y; Nakanishi M; Sumazaki R; Takada H
Int J Hematol; 2021 Apr; 113(4):493-499. PubMed ID: 33385293
[TBL] [Abstract][Full Text] [Related]
36. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
37. Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A.
Chuah MK; VandenDriessche T; Morgan RA
Hum Gene Ther; 1995 Nov; 6(11):1363-77. PubMed ID: 8573610
[TBL] [Abstract][Full Text] [Related]
38. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
Li YJ; Chen C; Zeng LY; Cao J; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
[TBL] [Abstract][Full Text] [Related]
39. GP64-pseudotyped lentiviral vectors target liver endothelial cells and correct hemophilia A mice.
Milani M; Canepari C; Assanelli S; Merlin S; Borroni E; Starinieri F; Biffi M; Russo F; Fabiano A; Zambroni D; Annoni A; Naldini L; Follenzi A; Cantore A
EMBO Mol Med; 2024 Jun; 16(6):1427-1450. PubMed ID: 38684862
[TBL] [Abstract][Full Text] [Related]
40. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
